ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2421

Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis

Tomohiro Koga1, Tomohito Sato1, Masataka Umeda2, Shoichi Fukui2, Ayako Nishino1, Shinya Kawashiri2, Naoki Iwamoto2, Kunihiro Ichinose2, Mami Tamai1, Tomoki Origuchi3, Hideki Nakamura2 and Atsushi Kawakami4, 1Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Animal models, Prognostic factors and rheumatoid arthritis (RA), T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease arising from a breakdown of peripheral tolerance, which leads to aberrant Th1- or Th17-driven immune reaction. Although aberrant Calcium/calmodulin-dependent protein kinase IV (CaMK4) activation has been implicated in the development of Th17 driven autoimmune diseases, the roles of CaMK4 activation in CD4+ T cells in the development and the pathogenesis of RA remain to be elucidated.

Objectives:

We sought to determine the significance of CaMK4 in the pathological condition of RA and to clarify whether the expression of CaMK4 can be a prognostic predictor for the progression of RA in daily practice.

Methods:

We treated collagen-induced arthritis (CIA) mice with KN-93, an inhibitor of CaMK4 and evaluated the clinical score, in vivo micro-computed tomography (ƒÊ-CT), and histological assessment. We examined the gene expression of Camk4 in CD4+ T cells from healthy controls (HC: n=20) and patients with active RA (n=21; median of DAS-ESR:5.14). We performed a multiple logistic regression analysis to explore the factors to predict poor response to treatment at 6 months.

Results:

Treatment of CIA mice with KN-93 results in a significant reduction of the clinical score of CIA severity and this is accompanied by decreased joint destruction evaluated by ƒÊ-CT and histology analysis. The expression of Camk4 mRNA in CD4+ T cells displayed significantly higher in RA patients than HC. Of note, the multiple logistic regression analysis revealed that the independent variables to predict poor response to treatment were the expression level of Camk4 mRNA in CD4 positive T cells from RA patients at baseline (OR= 24.7, 95%CI 2.76-634) and DAS-ESR at baseline (1-unit increase OR=4.40, 95%CI 1.67-18.5).

Conclusion:

Our results indicate that CaMK4 expression associates with RA development and its inhibition represents a novel therapeutic strategy for the treatment of RA.

Acknowledgements:

This work was supported by grants from the Leading Initiative for Excellent Young Researchers of the Ministry of Education, Culture, Sports, Science and Technology (to T.K: no. 16810055) and the Uehara Memorial Foundation (to T.K: no 201510047).


Disclosure: T. Koga, None; T. Sato, None; M. Umeda, None; S. Fukui, None; A. Nishino, None; S. Kawashiri, None; N. Iwamoto, None; K. Ichinose, None; M. Tamai, None; T. Origuchi, None; H. Nakamura, None; A. Kawakami, None.

To cite this abstract in AMA style:

Koga T, Sato T, Umeda M, Fukui S, Nishino A, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Origuchi T, Nakamura H, Kawakami A. Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/aberrant-expression-of-camk4-in-cd4-positive-t-cells-predicts-poor-response-to-treatment-in-patients-with-active-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/aberrant-expression-of-camk4-in-cd4-positive-t-cells-predicts-poor-response-to-treatment-in-patients-with-active-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology